$27.3M
1 filing since 2025 · latest Equity filed
Valthos is a New York-based biodefense company building frontier AI systems that identify biological threats and design medical countermeasures in real time. Its software rapidly characterizes biological sequences and updates medicines against emerging or engineered pathogens, aimed at compressing the time between detecting a threat and fielding a therapeutic. The company emerged from stealth in late 2025 with $30M from the OpenAI Startup Fund, Lux Capital and Founders Fund, and its team draws from Palantir, DeepMind, the Broad Institute and the Arc Institute.
What sets it apart
Couples real-time characterization of biological sequences with automated design of medical countermeasures, so detection and therapeutic response happen in one adaptive loop rather than as separate multi-year processes.
AI software that characterizes biological sequences as they are observed and designs or updates medical countermeasures against them in real time.
